Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 196,835 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ALL Clear all

Conditions: Mental Health
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: Not listed
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Interventions: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Infection
Interventions: Multivirus Specific T cells; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: AV-101, Placebo; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Garden Grove, California • Los Angeles, California • National City, California + 18 more

Conditions: Healthy Volunteers
Interventions: Genvoya Oral dose, Genvoya Crushed Dose; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vulvodynia, Vulvar Vestibulitis
Interventions: pregabalin; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Tocilizumab; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Hypercholesterolemia
Interventions: Ezetimibe 10 mg, Ezetimibe 5 mg; Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Older Persons Interested in Improving Their Brain Health
Interventions: Treatment as Usual, Cogtrastim Model; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Healthy
Interventions: APD791; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Osteoarthritis
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: To Determine Bioequivalence Under Fed Conditions
Interventions: Lisinopril; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Oral Complications of Radiation Therapy, Stage I Laryngeal Cancer, Stage II Laryngeal Cancer
Interventions: laser therapy, questionnaire administration; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Infantile Neuroaxonal Dystrophy
Interventions: RT001; Drug
Lead sponsor: Biojiva LLC; Industry
Eligibility: 18 Months to 10 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: San Francisco, California • Morristown, New Jersey

Conditions: Diabetes Mellitus, Cardiovascular Disease
Interventions: Low support, Medium support, High support, Comparison; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depressive Disorder
Interventions: SSR149415; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Overweight, Obesity
Interventions: 500 mL/day of a beverage providing approximately 625 mg catechins, Control beverage matched for energy and caffeine content; Dietary Supplement · Other
Lead sponsor: Provident Clinical Research; Other
Eligibility: 21 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: St. Petersburg, Florida • Bloomington, Indiana

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions: Insulin, Glyburide, Metformin; Drug
Lead sponsor: Maisa N. Feghali, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 3,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 117
States / cities: Tuscumbia, Alabama • Chula Vista, California • Concord, California + 95 more

Conditions: Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
Interventions: Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System; Biological · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Emergence Delirium, Strabismus
Interventions: Methadone; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 0 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jefferson, Louisiana

Conditions: Patellar Instability
Interventions: patellar stabilization; Procedure
Lead sponsor: Cleveland Clinic Akron General; Other
Eligibility: Up to 89 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Akron, Ohio

Search by objective public record fields.

Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Analysis of Crushed and Whole Tablet Genvoya

Pregabalin for the Treatment of Vulvodynia

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

A Comparison of Two Approaches to Developing Brain Health Programs

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Epidemiology of Osteoarthritis (OA) Pain

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss

Brain Control of Bimanual (Both Hands) Movements

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Methadone for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery

Computational Simulation of Patellar Instability